Back to Search
Start Over
Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro(a)LiFe study
- Source :
- Clinical Research in Cardiology Supplements
- Publication Year :
- 2015
- Publisher :
- Springer Science and Business Media LLC, 2015.
-
Abstract
- Elevated lipoprotein(a) (Lp(a)) has emerged as an important independent cardiovascular risk factor, and causal association has been accepted with adverse outcome in atherosclerotic disease. Lipoprotein apheresis (LA) can lower low-density lipoprotein (LDL)-cholesterol and Lp(a) by 60-70 % and is the final escalating therapeutic option in patients with hyperlipoproteinemias (HLP) involving LDL or Lp(a) particles. Major therapeutic effect of LA is preventing cardiovascular events. Stabilizing plaque morphology might be an important underlying mechanism of action. In Germany, since 2008, a reimbursement guideline has been implemented to establish the indication for LA not only for familial or severe forms of hypercholesterolemia but also for Lp(a)-HLP associated with a progressive course of cardiovascular disease, that persists despite effective treatment of other concomitant cardiovascular risk factors, i.e. isolated Lp(a)-HLP. The Pro(a)LiFe-study confirmed with a prospective multicenter design that LA can effectively reduce Lp(a) plasma levels and prevent cardiovascular events.
- Subjects :
- Male
Hyperlipoproteinemias
medicine.medical_specialty
Plaque stabilization
Plaque Stabilisierung
Disease
Prävention
Coronary artery disease
Article
Lipoprotein apheresis
Structural Biology
Germany
Internal medicine
Prevalence
medicine
Humans
Radiology, Nuclear Medicine and imaging
Longitudinal Studies
Risk factor
Molecular Biology
Aged
Angiology
biology
business.industry
Prevention
Therapeutic effect
General Medicine
Lipoprotein(a)
Guideline
Middle Aged
Cardiovascular disease
Atherosclerosis
medicine.disease
Koronare Herzerkrankung
Lipoprotein-Apherese
Treatment Outcome
Endocrinology
Blood Component Removal
biology.protein
Female
business
Kardiovaskuläre Erkrankung
Lipoprotein
Subjects
Details
- ISSN :
- 18610714 and 18610706
- Volume :
- 10
- Database :
- OpenAIRE
- Journal :
- Clinical Research in Cardiology Supplements
- Accession number :
- edsair.doi.dedup.....51ef3077af08b4424cab049db413ba77